Sector News

AZ spends $200M to expand US biologics site

November 24, 2014
Life sciences
AstraZeneca has announced plans to expand its US biologics manufacturing centre in Frederick, Maryland, spending more than $200 million to increase production in support of its “maturing pipeline”.
The company says the investment will help it keep pace “with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline”. The expansion, which is expected to be complete in mid-2017, will add 40,000 square feet of manufacturing, laboratory and administrative space and bring 300 new jobs to the site; the company currently employs over 3,000 people in Maryland.
Andrew Skibo, regional head of biologics supply for AstraZeneca, noted that the firm’s MedImmune unit “has a robust pipeline of more than 120 biologics, including more than 30 in clinical development. The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas”.
By Kevin Grogan
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]